RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Onconova Therapeutics Stock

Onconova Therapeutics ROE 2024

Onconova Therapeutics ROE

-1.78

Ticker

ONTX

ISIN

US68232V4059

WKN

A2N6RH

In 2024, Onconova Therapeutics's return on equity (ROE) was -1.78, a 165.04% increase from the -0.67 ROE in the previous year.

Onconova Therapeutics Aktienanalyse

What does Onconova Therapeutics do?

Onconova Therapeutics Inc. is a biopharmaceutical company focused on the development of drugs and therapies for the treatment of cancer. The company was founded in Pennsylvania in 1998 and is headquartered in Newtown, Pennsylvania. In 2013, the company went public and was listed on the NASDAQ. The history of Onconova Therapeutics began with the discovery of a new class of compounds known as precursor nucleotide analogs. These compounds were developed in collaboration with the National Cancer Institute (NCI) and showed promising results in cancer treatment. Onconova aims to develop innovative cancer therapies that allow for targeted attack on cancer cells without damaging healthy cells in the body. The company's research and development efforts focus on the discovery and development of new compounds and therapy approaches, as well as improving existing cancer treatments. The business model of Onconova Therapeutics is centered around building long-term partnerships with leading pharmaceutical companies, academic institutions, and research facilities. The company works closely with these partners to develop innovative therapies and drugs that meet the needs of cancer patients. Onconova has divided its product development into multiple areas to investigate the potential of its compounds in various therapy areas. The two main areas of focus for the company are myeloproliferative neoplasms (MPN) and oncology. Myeloproliferative neoplasms are a group of blood cancers that affect the bone marrow. Onconova Therapeutics has developed a promising class of compounds known as selective oral inhibitors (SOIs) that target the main drivers of MPNs and have shown positive results in clinical trials. The oncology division of the company focuses on the development of compounds for the treatment of solid tumors. Onconova has developed a targeted cancer therapy that focuses on inhibiting WNT signaling. This approach aims to allow for selective attack on cancer cells without damaging healthy cells in the body. In addition to these two areas, the company is also working on the development of compounds for the treatment of advanced tumors, lung cancer, and other types of cancer. The main product of Onconova Therapeutics is Rigosertib. Rigosertib is a selective oral inhibitor (SOI) specifically developed for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The drug is currently in the final phase III of testing by the FDA. In addition to Rigosertib, Onconova is conducting further clinical studies to investigate the effectiveness and safety of its cancer drugs. The company aims to develop innovative therapy options that help cancer patients overcome their disease and lead longer lives without the harmful effects of conventional cancer therapies. Overall, Onconova Therapeutics Inc. has a promising future as an innovative biopharmaceutical company. By continuing its research and development activities in multiple areas and developing new compounds and therapies, Onconova will continually contribute to improving the lives of cancer patients. Onconova Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Onconova Therapeutics's Return on Equity (ROE)

Onconova Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Onconova Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Onconova Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Onconova Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Onconova Therapeutics stock

What is the ROE (Return on Equity) of Onconova Therapeutics this year?

The ROE of Onconova Therapeutics this year is -1.78 undefined.

How has the Return on Equity (ROE) of Onconova Therapeutics developed compared to the previous year?

The ROE of Onconova Therapeutics has increased by 165.04% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Onconova Therapeutics?

A high ROE indicates that Onconova Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Onconova Therapeutics?

A low ROE can indicate that Onconova Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Onconova Therapeutics affect the company?

A change in ROE (Return on Equity) of Onconova Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Onconova Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Onconova Therapeutics?

Some factors that can influence Onconova Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Onconova Therapeutics pay?

Over the past 12 months, Onconova Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Onconova Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Onconova Therapeutics?

The current dividend yield of Onconova Therapeutics is .

When does Onconova Therapeutics pay dividends?

Onconova Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Onconova Therapeutics?

Onconova Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Onconova Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Onconova Therapeutics located?

Onconova Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Onconova Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Onconova Therapeutics from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Onconova Therapeutics pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Onconova Therapeutics in the year 2023?

In the year 2023, Onconova Therapeutics distributed 0 USD as dividends.

In which currency does Onconova Therapeutics pay out the dividend?

The dividends of Onconova Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Onconova Therapeutics

Our stock analysis for Onconova Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Onconova Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.